Tempus, a company founded by Eric Lefkofsky is now teaming up with the University of Chicago. The partnership involves Tempus providing patient data and data analysis to medical providers who are studying and treating cancer. Tempus will provide patient info and treatment info to doctors in an effort to learn from past treatments and past patients on what the most effective route for treating cancer is for new and existing patients. The data analytics company will also attempt to gather and store as much data on cancer patients and treatments as possible and give it to cancer researchers who can then glean information from the data to come up with customized solutions for patients.
Besides Tempus, Eric Lefkosky has founded numerous other companies. Lefkofsky is a venture capitalist who has his own venture capitalist investment bank called Lightbank. This firm invests in startups, products and new ideas, especially in the tech industry that have the potential to develop into big ideas, firms or products. Another company that Eric Lefkofsky has founded is called Media Ocean. This company uses software to streamline and organize marketing. One of the hall marks of Media Ocean is aggregating data from both the company, vendors, third parties and customers into one channel to create a central point from where all marketing can be based upon and begin to take root in.
Besides being involved in venture capitalist firms such as Lightbank and businesses such as Tempus and Media Ocean, Eric Lefkofsky is a leading philanthropist in the United States. Being a billionaire, Eric Lefkofsky realizes that giving back to the community is very important. To that end, Eric Lefkofsky has established the Eric and Liz Lefkofsky Family Foundation. This Foundation gives grants to medical research, education, the arts, and non-profit groups that raise awareness of key issues.
Oncology remains a sphere of medicine known for its numerous different facets. The complexities of oncology require those involved in the field to perform a great deal of research. Published research does need to be peer reviewed in order to ascertain value and validity. Oncotarget reflects a bold new sphere in the world of medical journals. Instead of publishing a medical journal in the traditional way, Oncotarget’s principals have chosen to craft an online open-source journal. Internet access to the articles published on the online community make them more accessible to those who would benefit greatly from their content.
Oncotarget never ceases to be cutting edge in its approach to presenting peer-reviewed material. Oncotarget’s Impact Factor is reflective of the immense popularity the articles and content published on the site. Impact factor, for those not familiar with the term, refers to how often a particular article has been cited in a particular year.
The impact factor figures associated with Oncotarget are fairly impressive. 2015 and 2016 saw an impact factor of about 5.008, which reflects a total of 10,452 cites. The overall five-year average of Oncotarget’s impact factor is 5.415. 2012 and 2013 featured 6.6+ impact factors. In the coming year of 2017, the numbers should continue to be impressive.
Read more: Like
Curiosity is likely now raised about Oncotarget and such curiosity leads many to want to learn more. Social media remains a reliable resource in which to check out updates and news. Oncotarget maintains a Facebook page, which is consistently updated with info. One recent update on Facebook reveals Oncotarget is instituting an “image forensic service” to boost “research integrity”. This would be quite the good move on behalf of the publishers and editors.
Oncotarget is likely to become very well known in the world of oncology research. Those interested in such research should keep tabs of this open-source publishing entity.
Read more about Oncotarget on URMC
Check YouTube about Oncotarget